New IBD drug candidate begins first human safety tests
NCT ID NCT07373457
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing an experimental drug called HW201877 in 104 healthy adults to see if it is safe and how the body processes it. The drug is being developed for inflammatory bowel disease (IBD), but this trial does not involve people with IBD. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mind over movement: can imagining exercise boost balance and brainpower?
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers
- Which pill works best? a trial puts elecoglipron formulations to the test
- Vitamin c may shield postmenopausal hearts without hormones
- Inhaled experimental drug targets tough lung infections
- Meal timing and stomach acid drugs may change how this experimental drug works